Fisher & Paykel Healthcare Limited

Named as a key player in 66 of our reports, across 33 regions and countries.

[1] ClinicalTrials.gov, Studies led by Fisher & Paykel Healthcare Limited or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Fisher & Paykel Healthcare Limited's markets

2

Markets where they are a key player. Each opens the market's statistics for every place we cover.

OTC & Nutraceuticals1

Medical Devices1

Recent reports naming Fisher & Paykel Healthcare Limited

Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.

All 66 reports

Companies they compete with most

Named as key players in the same markets as Fisher & Paykel Healthcare Limited (number of shared markets).

Public data

Free public data on Fisher & Paykel Healthcare Limited

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Home country
New Zealand
Stock listing
ASX: FPH

Source: Wikidata, Company record Q5454753. Retrieved 13 Nov 2026.

US device clearances

40 510(k) clearances and PMA approvals since 2015

Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.

See them on openFDA (opens in a new tab)

Trials over time

Studies Fisher & Paykel Healthcare Limited leads, by the year they started and their phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Fisher & Paykel Healthcare Limited or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Healthcare Topics

The topics of the markets Fisher & Paykel Healthcare Limited is in.

All healthcare topics

Search all reports for Fisher & Paykel Healthcare Limited All companies